TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Diastolic function differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Monocyte TNF-alpha release suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte numbers in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma total cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Grade 3 toxic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: percentage change in non-culprit coronary plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage change in lipid plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes within ±0.50 D of intended correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy index at 1 and 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates for astigmatic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients susceptible to transmitting HIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Effective dose of oxytocin infusion (ED95)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of parturients needing rescue oxytocin bolus or secondary uterotonic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent time per day in moderate and vigorous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain ratings during procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of healed lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for insulin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of ultrasound-detectable ovarian adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum melatonin levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intensity of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: acid-base balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensity rating of heartburn symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time to typical symptom perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion sensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine methylmalonic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Attenuation of pressor responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavior improvements in preschool-aged children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower stigma reported by parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: systemic exposure of DA‐8031
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete success defined as intraocular pressure ≤ 21 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Informed Consent Comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Goldmann-correlated intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Corneal resistance factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Corneal hysteresis measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: decrease in triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in LDL-cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of symptomatic UTI within 6 weeks of randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ANC recovery to 10 x 10(3)/mm3 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cancer recurrence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Family carer uncertainty in decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heat pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitory CPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost savings for patients
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Cost savings for providers
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time spent by hospital staff
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: thickness of stratum corneum and stratum granulosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: expression of tenascin and type I procollagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: adverse events (leukopenia, nausea, vomiting, stomatitis, alopecia)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of residual block (TOF ratio < 0.7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative pulmonary complications (POPC)
Endpoint domain: Adverse events/effects
Primary endpoint: Incident intralesional macular atrophy (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasopharyngeal acquisition of Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: degree of cephalgic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of autonomic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of OralCDx®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of OralCDx®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Debonding at the skin interface
Endpoint domain: Adverse events/effects
Primary endpoint: Pain perception during IV start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary fat intake and portion control classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-25OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infusion time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of 3-D tooth surface reproduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproduction of the subgingival tooth surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurocognitive composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attempt time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bone mineral density examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initiation of osteoporosis therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cumulative incidence of local failure (LF)
Endpoint domain: Mortality/survival
Primary endpoint: Mean savings per 1000 prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total savings to the healthcare system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: biochemically validated abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported quit rates at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Benefit from tamoxifen
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in platelet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in coagulation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volar tilt restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Obstruction Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of Smell Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: vergence adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAPP-A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate-severe OHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of liver and renal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Days of OHSS until resolution
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ANC or WBC recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma bilirubin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma nitrite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Deficits in sustained attention and executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SVG occlusion at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TMD (Temporomandibular Disorder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Heart rate variability indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inpatient treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean symptom-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean periodic dilatation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of dilations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean total scores on the Hamilton Rating Scale for Depression (HAM-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAF-F score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptance of IBIs for depression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increased vagal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in salivary IgG antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of shocks required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of dermal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Bishop score changes at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sublingual microflow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug exposure measured by area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean change in HbA(1c) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: depressive severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: re-hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality of Life (QOL) physical component subscale (PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life (QOL) general health (GH) subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tumour necrosis factor-alpha formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin-6 formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intracellular ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IgA, IgM and IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL(3) mass reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LDL(3)-to-LDL ratio reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Test scores on informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Willingness to pay (WTP) for P3P
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Willingness to pay (WTP) for usual care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Triglycerides levels postprandial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL cholesterol levels postprandial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemostatic effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet aggregation recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence intensity of GPIb/IX/V complex and GPIbalpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived functioning and well being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported outcomes improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Admission rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients requiring surgery submitted directly from emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Child adjustment problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relieving pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activation of descending pain inhibitory pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in minor errors
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in major errors
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in errors causing procedural delay
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of angiograms performed
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healing percentage at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periwound inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in appendicular skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced isometric maximum trunk‐extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SSS (Stress Score System)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SDS (Stress Defect Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of LV stress defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PFH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonprotein calories received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children developing episodes of otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean number of episodes of tube otorrhea per child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean estimated duration of episodes of tube otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pibrentasvir C max and AUC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 2/3 elevations in alanine aminotransferase, aspartate aminotransferase, and/or bilirubin
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 90% recovery of the first twitch in train-of-four (T(1) 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in motor performances at the finger tapping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of motor response coding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Freedom from progression to accelerated-phase or blast-crisis CML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fractional iodine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: amount of expansion of maxillary dentoalveolar structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drinking quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin elevation 2 h after perphenazine administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of peripheral edema
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum local analgesic dose of intrathecal bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children receiving all three shots of primary immunisation schedule before 12 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Patency of the infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in rhinorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nasal itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery at <28 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Apparent oral clearance of (R)-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of (R)-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution at steady-state of (R)-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes